FDA 483 - California Pharmacy & Compounding Center - December 17, 2018

This FDA Form 483 document outlines observations made during an inspection of a manufacturing facility. The inspection identified four key deficiencies related to the firm's quality system and manufacturing processes.

Observation 1 indicates the firm failed to establish an adequate quality control unit. This suggests a fundamental weakness in the oversight and management of quality-related activities.

Observation 2 notes that the manufacturing process for Product X was not adequately validated. This is a critical finding as it implies the process may not consistently produce a product meeting its predetermined specifications and quality attributes, potentially impacting product efficacy and safety.

Observation 3 highlights a failure to maintain proper records of equipment cleaning and maintenance. This deficiency can lead to cross-contamination risks and equipment malfunctions, affecting product quality and safety.

Finally, Observation 4 states that the firm did not conduct adequate testing of raw materials before their use in production. This poses a significant risk as untested raw materials could introduce contaminants or incorrect components into the final product, compromising its quality, safety, and effectiveness.

Collectively, these observations point to systemic issues within the firm's quality management system, impacting various stages from raw material control to process validation and overall quality oversight.